JUNS Latest Press Releases

-- October 6, 2026 --

Jupiter Neurosciences Announces First Patient Dosed in Phase 2a RESET Trial in Parkinson's Disease and Exploration of Strategic Options to Maximize Shareholder Value Globe Newswire 11:15 AM

-- August 21, 2026 --

Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering Globe Newswire 12:20 PM

PharmAla Biotech Provides Corporate Update: U.S. Patent Granted Covering Novel Enantioselective Processes, Decision on APA-01, and Engagement of Canaccord Genuity as Exclusive Investment Banking Partner Globe Newswire 7:00 AM

-- August 5, 2026 --

Jupiter Neurosciences, Inc. Announces Reverse Stock Split Globe Newswire 8:00 AM

-- July 21, 2026 --

Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million Globe Newswire 7:13 AM

PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive U.S. Rights to ALA-002 Globe Newswire 7:00 AM

-- July 7, 2026 --

Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson Globe Newswire 8:58 AM

-- June 10, 2026 --

Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream Globe Newswire 7:00 AM

-- June 9, 2026 --

Presenting on Emerging Growth Conference 93 Day 1 on June 10; Register to live stream Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes